A new poll finds that many Americans remain hesitant to buy electric vehicles. The AP-NORC/EPIC poll found only about 2 in 10 ...

(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Adolescents and young adults with preexisting autoimmune disease are more likely to develop type 1 diabetes than those ...

Băi wén bù rú yī jiàn“Seeing for oneself is a hundred times better than hearing from others.”Chinese Proverb from the Book of ...

Biosimilars saved Italy €3.1 billion in drug spending over a decade as uptake reached 80% of biologic use, according to the ...

Biocon Biologics recently announced that it would manufacture and supply insulin glargine pens to Civica under a multi-year ...

The United States Rapid Acting Insulin Market is poised for significant growth, increasing from US$ 2.32 Billion in 2024 to US$ 3.40 Billion by 2033, with a CAGR of 4.33%. Key growth drivers include ...

Lawmakers have focused on the high cost of diabetes drugs. The announcement will make state-branded insulin available two years later than the governor originally promised.

Utah-based Civica will begin selling a type of long-acting insulin on Jan. 1, 2026, although it will not come from the nonprofit drug maker’s Petersburg facility. Civica announced Thursday it has ...

LOS ANGELES (AP) — Gov. Gavin Newsom said Thursday that California will begin selling affordable insulin under its own label on Jan. 1, nearly three years after he first announced a partnership to ...